Lung Adenocarcinoma - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lung Adenocarcinoma - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Lung Adenocarcinoma - Pipeline Review, H2 2015', provides an overview of the Lung Adenocarcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Lung Adenocarcinoma Overview 9
Therapeutics Development 10
Pipeline Products for Lung Adenocarcinoma - Overview 10
Pipeline Products for Lung Adenocarcinoma - Comparative Analysis 11
Lung Adenocarcinoma - Therapeutics under Development by Companies 12
Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 14
Lung Adenocarcinoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Lung Adenocarcinoma - Products under Development by Companies 18
Lung Adenocarcinoma - Products under Investigation by Universities/Institutes 19
Lung Adenocarcinoma - Companies Involved in Therapeutics Development 20
Amgen Inc. 20
Astex Pharmaceuticals, Inc. 21
AstraZeneca Plc 22
AVEO Pharmaceuticals, Inc. 23
Axelar AB 24
Bayer AG 25
Boehringer Ingelheim GmbH 26
Eisai Co., Ltd. 27
Genentech, Inc. 28
Hanmi Pharmaceuticals, Co. Ltd. 29
Immunomedics, Inc. 30
Incyte Corporation 31
Johnson & Johnson 32
Morphotek, Inc. 33
Pfizer Inc. 34
Sanofi 35
VG Life Sciences, Inc. 36
Vichem Chemie Research Ltd. 37
Lung Adenocarcinoma - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 43
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
afatinib dimaleate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AV-203 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AXL-1717 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
AZD-6738 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BAY-1163877 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
dacomitinib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
DBPR-112 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
EB-102 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
farletuzumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
hydroxychloroquine + sorafenib tosylate - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JNJ-42756493 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
lenvatinib - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MAG-Tn3 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
poziotinib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Recombinant Protein to Agonize Interferon Lamda Receptor 1 for Oncology and Infectious Diseases - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ruxolitinib phosphate - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
SAR-408701 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecule for Cancer - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Small Molecule to Inhibit EGFR for Non-Small Cell Lung Cancer and Lung Adenocarcinoma - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SNX-5422 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
solitomab - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
TdCyd - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Vaccine for Oncology - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Vaccine to Target CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
VAL-401 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Lung Adenocarcinoma - Recent Pipeline Updates 99
Lung Adenocarcinoma - Dormant Projects 129
Lung Adenocarcinoma - Product Development Milestones 130
Featured News & Press Releases 130
May 29, 2015: Spectrum Pharmaceuticals Highlights Abstract of Clinical Data For Poziotinib at the 2015 ASCO Annual Meeting 130
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 131
Disclaimer 132

List of Tables

Number of Products under Development for Lung Adenocarcinoma, H2 2015 10
Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Products under Development by Companies, H2 2015 18
Products under Investigation by Universities/Institutes, H2 2015 19
Lung Adenocarcinoma - Pipeline by Amgen Inc., H2 2015 20
Lung Adenocarcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 21
Lung Adenocarcinoma - Pipeline by AstraZeneca Plc, H2 2015 22
Lung Adenocarcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 23
Lung Adenocarcinoma - Pipeline by Axelar AB, H2 2015 24
Lung Adenocarcinoma - Pipeline by Bayer AG, H2 2015 25
Lung Adenocarcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 26
Lung Adenocarcinoma - Pipeline by Eisai Co., Ltd., H2 2015 27
Lung Adenocarcinoma - Pipeline by Genentech, Inc., H2 2015 28
Lung Adenocarcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 29
Lung Adenocarcinoma - Pipeline by Immunomedics, Inc., H2 2015 30
Lung Adenocarcinoma - Pipeline by Incyte Corporation, H2 2015 31
Lung Adenocarcinoma - Pipeline by Johnson & Johnson, H2 2015 32
Lung Adenocarcinoma - Pipeline by Morphotek, Inc., H2 2015 33
Lung Adenocarcinoma - Pipeline by Pfizer Inc., H2 2015 34
Lung Adenocarcinoma - Pipeline by Sanofi, H2 2015 35
Lung Adenocarcinoma - Pipeline by VG Life Sciences, Inc., H2 2015 36
Lung Adenocarcinoma - Pipeline by Vichem Chemie Research Ltd., H2 2015 37
Assessment by Monotherapy Products, H2 2015 38
Assessment by Combination Products, H2 2015 39
Number of Products by Stage and Target, H2 2015 41
Number of Products by Stage and Mechanism of Action, H2 2015 44
Number of Products by Stage and Route of Administration, H2 2015 47
Number of Products by Stage and Molecule Type, H2 2015 49
Lung Adenocarcinoma Therapeutics - Recent Pipeline Updates, H2 2015 99
Lung Adenocarcinoma - Dormant Projects, H2 2015 129